臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52570160 線上人數 : 844 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lin c c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 1301-1310 / 2549 (共255頁)
<< < 126 127 128 129 130 131 132 133 134 135 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-05-26T09:26:57Z	A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies	Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:55Z	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer	Chih-Hsin Yang;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:55Z	Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy	Chih-Hsin Yang;Shih J.Y;Lin C.C;Liao B.C; Liao B.C; Lin C.C; Shih J.Y; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:52Z	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis	Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Chang C.-H;Chen Y.-F;Lin C.-C;Lee J.-H;Liao B.-C; Liao B.-C; Lee J.-H; Lin C.-C; Chen Y.-F; Chang C.-H; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:48Z	Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study	Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K.
臺大學術典藏	2020-05-26T09:26:47Z	151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs	Chih-Hsin Yang;Yu C.-J;Chang Y.-C;Shih J.-Y;Ho C.-C;Lee Y.-F;Lin S.-Y;Lin C.-C;Bai Y.-Y;Liao B.-C; Liao B.-C; Bai Y.-Y; Lin C.-C; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:45Z	Safety of gefitinib in non-small cell lung cancer treatment	Chih-Hsin Yang;Lin C.-C;Lee J.-H;Hsiue E.H.-C; Hsiue E.H.-C; Lee J.-H; Lin C.-C; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:43Z	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors	Chih-Hsin Yang;Lee J.-H;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; Lee J.-H; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:43Z	Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer	Chih-Hsin Yang;Lin C.-C;Lee J.-H;Hsiue E.H.-C; Hsiue E.H.-C; Lee J.-H; Lin C.-C; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:38Z	Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component	J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A.

顯示項目 1301-1310 / 2549 (共255頁)
<< < 126 127 128 129 130 131 132 133 134 135 > >>
每頁顯示[10|25|50]項目